SRSF2 and acute myeloid leukemia: Patients with ≤2 aneuploidies (n = 233, 11%), enriched for “MDS-related”16,17 cytogenetic abnormalities clustered with secondary AML type mutations (sAML)16 such as SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2, as well as novelly described here, RUNX1, SETBP1, and MLLPTD mutations.